Petefészekrák: vizsgálatok itt: Kína
184 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleTorvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
- Where
- Anyang, Beijing, Binzhou Shi, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Huangpu District, Jinan, Linyi, Luoyang, Luzhou, Nanchang, Nanjing, Nanning, Neijiang, Shanghai, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Weifang, Wenzhou, Wuhan, Xinxiang, Xuzhou
- Életkor
- 18 év and over
- People
- 950 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00 - 1. fázisTaking peopleA Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
- Where
- Chengdu, Dalian, Fuzhou, Shanghai
- Életkor
- 18 év and over
- People
- 30
- Run by
- Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.
See details and how to joinNCT07923214 - 1/2. fázisTaking peopleRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Guangdong, Hangzhou, Henan, Hubei, Nanchang, Shanghai, Shanxi, Shengyang, Tianjin
- Életkor
- 18 év and over
- People
- 952 worldwide
- Run by
- Genmab
See details and how to joinNCT05579366 - 1. fázisTaking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Beijing, Guangzhou, Shanghai
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - 2. fázisTaking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Beijing, Changsha, Hangzhou, Shanghai
- Életkor
- 18 év and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - 1. fázisTaking peopleA Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 340 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00 - 3. fázisTaking peopleA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Beijing, Changchun, Changde, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Lanzhou, Luoyang, Nanjing, Nanning, Shanghai, Shantou, Shenzhen, Tianjin, Wuhan
- Életkor
- 18 év and over
- People
- 1630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00 - 2. fázisTaking peopleNeoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 82
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07432594 - 3. fázisTaking peopleClinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer
- Where
- Beijing, Yunnan, Zhejiang
- Életkor
- 18 év and over
- People
- 420
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07779538 - 3. fázisTaking peopleAn Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
- Where
- Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xi’an, Zhengzhou
- Életkor
- 18 év and over
- People
- 82
- Run by
- Genmab
See details and how to joinNCT07604766 - 1/2. fázisCsak meghívásosIntervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors
- Where
- Shenzhen
- Életkor
- 10 év to 80 év
- People
- 20
- Run by
- Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03393962 - 1. fázisTaking peopleA Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 128
- Run by
- TJ Biopharma Co., Ltd.
See details and how to joinNCT07715747 - 2. fázisTaking peopleDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Beijing, Changsha, Chengdu, Dongguan, Henan, Hubei, Shanghai, Shenyang, Wuhan, Xi'an, Xinxiang, Xuzhou
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - 3. fázisTaking peopleEfficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer
- Where
- Hefei
- Életkor
- 18 év to 75 év
- People
- 100
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT06542549 - 3. fázisTaking peopleStudy of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi’an, Yantai, Zhengzhou
- Életkor
- 18 év and over
- People
- 582 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00 - 2/3. fázisTaking peopleA Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Where
- Beijing, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanning, Shanghai, Tianjin, Wuhan, Xi’an
- Életkor
- 18 év and over
- People
- 860 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Chengdu, Guangzhou
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 1. fázisTaking peopleA Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 96
- Run by
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT06531486 - No phaseTaking peopleFeasibility of the "One-Finger Technique" for Identifying the Upper Left Ureter During Para-Aortic Lymphadenectomy
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 40
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07895212 - 1/2. fázisTaking peopleA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Where
- Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Taizhou, Tianjin, Wuhan, Xi’an, Xinxiang, Zhengzhou
- Életkor
- 18 év and over
- People
- 862 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT05914116 - 1/2. fázisTaking peopleA Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 150 worldwide
- Run by
- Phrontline Biopharma
See details and how to joinNCT07778498 - 3. fázisTaking peopleTorvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
- Where
- Beijing, Chengdu, Guangdong Province, Guangzhou, Hangzhou, Nanchang, Wuhan, Zhengzhou
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07816666 · EU 2026-526776-23-00 - No phaseTaking people68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 50
- Run by
- Peking University Third Hospital
See details and how to joinNCT07760012 - 1/2. fázisTaking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Beijing, Changsha, Chongqing, Guangzhou, Kunming, Shandong
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - 1/2. fázisTaking peoplePhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Where
- Beijing, Fuzhou, Guangzhou, Shandong, Shanghai
- Életkor
- 18 év and over
- People
- 233 worldwide
- Run by
- Ensem Therapeutics
See details and how to joinNCT06993844